國立高雄大學圖資館 |

Language: English

Back

Angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockersa critical analysis of antihypertensive strategies : a machine-generated literature overview /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockersedited by Mukesh Nandave.
Reminder of title:	a critical analysis of antihypertensive strategies : a machine-generated literature overview /
other author:	Nandave, Mukesh.
Published:	Singapore :Springer Nature Singapore :2024.
Description:	xiv, 602 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	Angiotensin converting enzymeInhibitors.
Online resource:	https://doi.org/10.1007/978-981-97-7380-0
ISBN:	9789819773800$q(electronic bk.)

Angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockersa critical analysis of antihypertensive strategies : a machine-generated literature overview /
Angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockersa critical analysis of antihypertensive strategies : a machine-generated literature overview /[electronic resource] :edited by Mukesh Nandave. - Singapore :Springer Nature Singapore :2024. - xiv, 602 p. :ill., digital ;24 cm.

Chapter 1_ Introduction of the renin-angiotensin-aldosterone system (RAAS) -- Chapter 2_ Role of anti-hypertensive agents in cardiovascular disorders -- Chapter 3_ (ACE) Angiotensin-converting enzyme inhibitors: Preferred RAAS inhibitor in high-risk patients as compared to angiotensin receptor blockers (ARBs) -- Chapter 4_ Role of (ACE) angiotensin-converting enzyme inhibitors in transforming renin-angiotensin system -- Chapter 5_ The effect of (ACE) Angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers on insulin resistance in hypertensive patients -- Chapter 6_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure -- Chapter 7_ Immunomodulator activity of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients -- Chapter 8_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peripheral artery disease -- Chapter 9_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in covid-19 patients -- Chapter 10_ Recent trends in the management of hypertension through RAAS inhibition.

The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the editor(s) of this book. The editor(s) of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that these are extractive auto-summaries, which consist of original sentences, but are not representative of its original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here, and that machine-generated books are still at an experimental stage.

ISBN: 9789819773800$q(electronic bk.)

Standard No.: 10.1007/978-981-97-7380-0doiSubjects--Topical Terms:

711548
Angiotensin converting enzyme
--Inhibitors.

LC Class. No.: RC684.A53

Dewey Class. No.: 616.1061

Angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockersa critical analysis of antihypertensive strategies : a machine-generated literature overview /
LDR:02926nmm a2200325 a 4500 001 671540
003 DE-He213
005 20241026125733.0
006 m d
007 cr nn 008maaau
008 250325s2024 si s 0 eng d
020 $a 9789819773800$q(electronic bk.)
020 $a 9789819773794$q(paper)
024 7 $a 10.1007/978-981-97-7380-0 $2 doi
035 $a 978-981-97-7380-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC684.A53
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 616.1061 $2 23
090 $a RC684.A53 $b A588 2024
245 0 0 $a Angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers $h [electronic resource] : $b a critical analysis of antihypertensive strategies : a machine-generated literature overview / $c edited by Mukesh Nandave.
260 $a Singapore : $b Springer Nature Singapore : $b Imprint: Springer, $c 2024.
300 $a xiv, 602 p. : $b ill., digital ; $c 24 cm.
505 0 $a Chapter 1_ Introduction of the renin-angiotensin-aldosterone system (RAAS) -- Chapter 2_ Role of anti-hypertensive agents in cardiovascular disorders -- Chapter 3_ (ACE) Angiotensin-converting enzyme inhibitors: Preferred RAAS inhibitor in high-risk patients as compared to angiotensin receptor blockers (ARBs) -- Chapter 4_ Role of (ACE) angiotensin-converting enzyme inhibitors in transforming renin-angiotensin system -- Chapter 5_ The effect of (ACE) Angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers on insulin resistance in hypertensive patients -- Chapter 6_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure -- Chapter 7_ Immunomodulator activity of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients -- Chapter 8_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peripheral artery disease -- Chapter 9_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in covid-19 patients -- Chapter 10_ Recent trends in the management of hypertension through RAAS inhibition.
520 $a The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the editor(s) of this book. The editor(s) of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that these are extractive auto-summaries, which consist of original sentences, but are not representative of its original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here, and that machine-generated books are still at an experimental stage.
650 0 $a Angiotensin converting enzyme $x Inhibitors. $3 711548
650 1 4 $a Pharmacology. $3 218135
650 2 4 $a Drug Safety and Pharmacovigilance. $3 701740
650 2 4 $a Biomedical Research. $3 243625
650 2 4 $a Medical Biochemistry. $3 274286
650 2 4 $a Therapeutics. $3 218144
700 1 $a Nandave, Mukesh. $3 978240
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-981-97-7380-0
950 $a Medicine (SpringerNature-11650)